Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06580223
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-28
Brief Title:
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma A Prospective Multicenter Open-Label Randomized Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to evaluate the efficacy and safety of aspirin and rivaroxaban in thromboprophylaxis in Chinese MM patients at high risk for MM-associated VTE
Detailed Description:
Venous thromboembolism VTE is one of the most common and dangerous complications of Multiple Myeloma MM The occurrence of VTE can disrupt treatment plans compromise patients quality of life and even threaten their lives presenting significant challenges in clinical management Although several guidelines recommend risk-stratified thromboprophylaxis there is a deficiency in prospective validation and most initial studies were conducted in Western cohorts This prospective multicenter open-label randomized study aims to compare the efficacy and safety of aspirin or rivaroxaban in preventing VTE in Chinese MM patients who are at high risk for VTE
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None